SHL Medical

SHL Medical SHL Medical is a pioneering leader in advanced self-injection solutions such as autoinjectors and pen injectors.

SHL Medical is a pioneering leader in self-injection solutions, such as autoinjectors. Headquartered in Switzerland with sites across three continents, we offer end-to-end services, from design and development to final assembly, labeling, and packaging, partnering with pharma companies to deliver self-injection systems that enable patients’ independence. View SHL Medical trademarks: https://www.shl-medical.com/trademarks

Today, on International Women in Engineering Day, we recognize the knowledge, creativity, and leadership that women acro...
23/06/2026

Today, on International Women in Engineering Day, we recognize the knowledge, creativity, and leadership that women across SHL Medical bring to engineering every day.

Across our global teams, we are committed to creating an environment where women can grow, lead, and succeed, strengthening representation in an engineering-driven industry.

In Switzerland, our partnership with Advance supports mentorship programs that help unlock women's leadership potential. The impact is clear: more women are stepping into leadership roles. We have reached our 2025 target of 30% representation of women in senior management and continue to build on that progress.

At the same time, we are investing in the next generation. From mentorship initiatives to hands-on activities like Introducing Girls to Engineering Day in Sweden, we are creating opportunities for young women to explore careers in healthcare manufacturing and see what is possible.

From engineering and automation to quality and project leadership, our teams are advancing reliable drug delivery solutions every day, moving innovation from development into production and improving outcomes for patients worldwide.

Ten years of commercial success does not happen by chance. ​Built on over 20 years of hands-on autoinjector expertise, M...
22/06/2026

Ten years of commercial success does not happen by chance.
​
Built on over 20 years of hands-on autoinjector expertise, Molly’s creation was driven by a clear ambition: to balance reliability with user-centric design.
​
Since its first commercial launch in 2016, Molly has evolved into a global platform supporting 22 combination products across nearly 30 indications, with scalable manufacturing capabilities across three continents.
​
Over the past decade, more than 210 million Molly devices have reached patients worldwide. In 2025 alone, 90 million devices were delivered, reflecting performance at scale and across commercial use.
​
Reaching this milestone required more than innovation. It took capabilities built across development, industrialization, manufacturing, and supply, together with years of collaboration with pharma partners to support commercial delivery.
​
Today, Molly stands as a proven platform built through commercial experience, manufacturing scale, and real-world performance.
​
Learn more about Molly and its track record: https://bit.ly/4osULIQ
​

A device can pass a usability test and still feel uncomfortable, confusing, or difficult to use. That difference matters...
19/06/2026

A device can pass a usability test and still feel uncomfortable, confusing, or difficult to use. That difference matters in self-injection.

For patients using autoinjectors, confidence can come down to very practical details: how much force is needed, how the device feels in hand, whether each step is clear, and how the experience changes in real-world settings.

In our latest blog, we look at how user-centered design and usability engineering can support a more comfortable user experience: https://bit.ly/4efDa2B

18/06/2026

For many biologics, stability begins long before administration.

Following her recent presentation in San Diego, Dr. Nina Fetz revisits one of the key reasons lyophilization matters in biologic drug development.

In this clip, she explains why freeze-drying is used to support stability and shelf life for many biologics, and what that means for reconstitution-ready delivery solutions across the biologics pipeline.

Market shifts are not the only thing that tests a combination product program. Sometimes, the bigger test is whether ear...
17/06/2026

Market shifts are not the only thing that tests a combination product program. Sometimes, the bigger test is whether earlier decisions left enough room to adapt.

Usability, manufacturability, compliance, packaging, and sustainability can all seem like separate workstreams during development. But once a product moves toward commercial supply, those decisions start to connect. They shape what can change quickly, what needs additional evidence, and where complexity begins to show.

On June 29 in Basel, SHL Medical and Pharma Services will discuss how human-centered device and packaging design can help teams think through these tradeoffs earlier and build more sustainable, scalable combination product strategies.

Join us in Basel for the discussion.
Register here: https://bit.ly/4dBQRKd

Across discussions on the floor at CPHI and PMEC China, there is strong interest in how localized strategies, establishe...
16/06/2026

Across discussions on the floor at CPHI and PMEC China, there is strong interest in how localized strategies, established device development pathways, and scalable manufacturing can support cost-conscious commercialization in China.

Visitors were also particularly interested in Reunite and its approach to lyophilized drug delivery, including its automated reconstitution mechanism and integration of Needle Isolation Technology (NIT).

We’ll be at Booth for two more days in Shanghai. Connect with our team to discuss how our device platforms and regional market expertise can support your next program.

Just two weeks until our webinar with Kymanox! Device platforms have become a cornerstone of combination product develop...
15/06/2026

Just two weeks until our webinar with Kymanox!

Device platforms have become a cornerstone of combination product development, enabling pharmaceutical companies to leverage a single platform across multiple products and biosimilars to accelerate development and reduce risk. But what happens when market needs require the platform to evolve?

Join Dr. Nina Fetz of SHL Medical and Katy Rommel, PhD, of Kymanox for a webinar exploring practical strategies for managing platform evolution and the associated regulatory considerations in drug-device combination products.

📌 June 22, 2026 | 3 PM (CEST) / 9 AM ET

Register for the webinar: https://bit.ly/4dZVjCw

Behind every blood donation is a simple decision to help someone we may never meet.In recognition of , colleagues from ...
14/06/2026

Behind every blood donation is a simple decision to help someone we may never meet.

In recognition of , colleagues from US and Taiwan facilities joined local blood donation initiatives, taking a moment from the workday to support patients and healthcare systems in a very direct way.

For some, it was a regular habit. For others, it was their first time donating. But across both sites, the idea was the same: small acts of care can mean more time, more treatment options, or another chance to recover for someone else.

This year’s theme, “One Drop of Humanity. Give Blood. Save Lives,” feels especially fitting. At SHL Medical, we often speak about supporting patients through our work, but moments like this bring that purpose much closer to home: sometimes, supporting patients also means taking a moment to show up for someone else.

Thank you to our colleagues for rolling up their sleeves and helping turn that message into action. 💙

Across two events in June, our teams joined conversations that went beyond the device alone. The real questions were abo...
12/06/2026

Across two events in June, our teams joined conversations that went beyond the device alone. The real questions were about how delivery decisions affect the full path to commercialization.

For large-volume delivery, that means thinking beyond fill volume. Primary container choice, device design, fill-finish, supply, and scalability all need to be aligned earlier.

For lyophilized drug delivery, the question is just as practical. If reconstitution remains difficult to manage, it can limit how far a therapy can move toward self-administration.

This is where platform strategy and partner collaboration become important. The goal is to help pharma teams make delivery decisions that hold up beyond development, through manufacturing, commercialization, and real-world use.

Thank you to everyone who shared perspectives with us in Basel and San Diego. We look forward to continuing the discussion in October.

At the intersection of clinical development and device design, the Molecule-Independent Device Bridging Approach (MIDBA)...
11/06/2026

At the intersection of clinical development and device design, the Molecule-Independent Device Bridging Approach (MIDBA) was recently endorsed by the European Medicines Agency (EMA) to reduce the burden of dedicated device bridging studies for certain monoclonal antibody programs.

Its applicability is defined by scientific, clinical, and device-specific criteria that must be met.

Our latest technical memo explores how Molly and MIDBA work together to streamline monoclonal antibody clinical development, and discusses the scientific foundation of the framework which SHL Medical is proud to have played a role in.

As we mark 10 years since Molly’s first approval, MIDBA highlights the evolving role that established autoinjector platforms can play in a changing regulatory landscape for biologics development.

Download the memo: https://bit.ly/4aaN0lh

Adresse

Gubelstrasse 22
Zug
6300

Webseite

,

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von SHL Medical erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Service Kontaktieren

Nachricht an SHL Medical senden:

Verknüpfungen

Teilen